Growth of the medicinal cannabis market in Brazil: a revolution in numbers and health

The medicinal cannabis market in Brazil has seen remarkable growth in recent years, reflecting a significant shift in the perception and acceptance of the plant's therapeutic use. This increase is driven by more flexible regulations, scientific advancements, and a growing demand for natural treatment alternatives. According to data from Kaya Mind, a company specialized in cannabis market research, the sector generated approximately R$ 200 million in 2022 and projects an annual growth of 30% over the next five years.

The National Health Surveillance Agency (Anvisa) plays a crucial role in this scenario. Since the implementation of RDCs 327/2019 and 660/2022, which regulate the production, sale in pharmacies, and importation of cannabis-based products in the country, there has been a significant increase in authorizations for medications containing cannabidiol (CBD) and tetrahydrocannabinol (THC). In 2023, Anvisa registered over 40 new cannabis-based products, a 50% jump from the previous year.

Pollyana Raquel Segantine, laboratory manager at Teuto, a pharmaceutical company investing in cannabis, shared her insights on the impact of this market growth and the innovations the company is bringing to the sector.

In summary, the growth of the medicinal cannabis market in Brazil is not just a reflection of regulatory changes but also a testament to the proven therapeutic effectiveness of these products. As more patients report significant improvements in their health conditions, the trend is for the sector to continue expanding, bringing benefits to both public health and the country's economy.